Health Canada
Symbol of the Government of Canada

Common menu bar links

About Health Canada

Access to Information Requests Completed – October 2013

The following is a list of Access to Information requests processed by Health Canada. The list is not all-inclusive. The list contains requests completed for which documents have been retrieved or treated. The list is provided in chronological order, by month and year, and by request number. (Requests focusing on personal information or third party proprietary information are not included.)

If you wish to obtain a copy of the records released in response to these requests informally, you may contact the Access to Information and Privacy Division.

AER
Adverse Reaction Report (Adverse Event)
DIN
Drug Identification Number
DIN-HM
Homeopathic Medicine Number
NPN
Natural Product Number
For the month of October 2013
Request # Summary of Requests Status of Completed Request Number of Pages Disclosed
A-2010-01449 Information regarding Voluven, DIN 02278057 by FRESENIUS KABI CANADA, A DIVISION OF CALEA LTD. Disclosed in part 326
A-2011-00914 All documents about the Regulatory Cooperation Council meeting between Canada and the United States on July 14, 2011. (Apr 1, 2011 to Aug 31, 2011). Disclosed in part 998
A-2011-01139 Documents on immunity claims for infant formulas. (Jan 1, 2010 to Nov. 30, 2011). Disclosed in part 36
A-2011-01162 Records retrieved but not processed under A-2010-00488 (All minutes of Toy Committee meetings from May 23, 2009 to July 7, 2010.) Disclosed in part 1,632
A-2011-01595 Reviewer reports regarding Combivir by Glaxo Wellcome Biocherm Inc. Disclosed in part 248
A-2011-01627 Information regarding Drixoral No Drip Extra Moisturizing, DIN 02245575. Disclosed in part 77
A-2012-00115 Information regarding Urex-Cap-5; Fem-Dophilus, NPN 80012937 by Chr. Hansen A/S. Disclosed in part 120
A-2012-01106 Documents related to a loss listed in the 2011 Public Accounts of Canada document for $260,827 for false or fraudulent claims for contributions. Disclosed in part 2
A-2012-01107 Documents related to a loss listed in the 2011 Public Accounts of Canada document for $160,491 for fraudulent claims for benefits. Disclosed in part 65
A-2012-01108 Documents related to a loss listed in the 2011 Public Accounts of Canada document for $294,466 for fraudulent claims for benefits. Disclosed in part 19
A-2012-01412 A copy of the Consumer Product and Safety Directorate's new database known as RADAR (Regulatory Action Depot/ Dépôt d'actions réglementaires). (Jul 1, 2011 to Dec 31, 2012). All disclosed 1,284
A-2012-01629 AERs for Humalog. Report numbers: 000406704 and 000437671. Disclosed in part 6
A-2012-01714 AERs for Propecia. Report numbers: 000467070, 000418883, 000408004, 000374017, 000376737, 000363203, 000336888, 000162769 and 000208090. Disclosed in part 25
A-2012-01735 AER for Nexavar. Report number: 000472552. All disclosed 2
A-2013-00064 Information regarding Lyssin, DIN-HM 80005337 by Natural Equivalents Incorporated. Disclosed in part 33
A-2013-00065 Information regarding Pleo Sanklebs (Drops 6x) and Pleo Sanklebs (Portable Sips 6x), DIN-HM 80007380 and 80007383 by Biomed International. Disclosed in part 51
A-2013-00067 Information regarding the following:
Medorrhinum-Injeel, DIN-HM 80013673
Staphylococcus-Injeel, DIN-HM 80013674
Vaccininum-Injeel, DIN-HM 80012940
(Jan 1 2008 to Dec 31 2012)
Disclosed in part 183
A-2013-00089 Information regarding Adrien Gagnon Collagen(E) Triple Action; Adrien Gagnon Genercoll, NPN 80026985 by Santé Naturelle (A.G.) Ltée. Disclosed in part 67
A-2013-00090 Information regarding Adrien Gagnon Super Energex + Ampoules, NPN 80027332 by Santé Naturelle (A.G.) Ltée. Disclosed in part 105
A-2013-00091 Information regarding Adrien Gagnon Super Energex + Ampoules, NPN 80025836 by Santé Naturelle (A.G.) Ltée. Disclosed in part 109
A-2013-00092 Information regarding Adrien Gagnon Super Energex Capsules, NPN 80024838 by Santé Naturelle (A.G.) Ltée. Disclosed in part 169
A-2013-00203 AERs for Strattera. Report numbers: 000467737, 000468698, 000475315, 000476165 and 000484671. Disclosed in part 5
A-2013-00235 Controlled substances status reports. (Jan 1, 2013 to May 21, 2013). Disclosed in part 5,146
A-2013-00256 AERs for Synthroid. Report numbers: 000468536, 000476194, 000479401, 000483283 and 000484891. All disclosed 16
A-2013-00266 Draft documents pertaining to Safety Code 6 Disclosed in part 100
A-2013-00343 Information regarding Isopropyl Alcohol 99%, NPN 00167657 by RW Packaging Ltd. Disclosed in part 42
A-2013-00344 Information regarding Glycerin, NPN 00492434 by RW Packaging Ltd. Disclosed in part 56
A-2013-00346 Information regarding Hydrogen Peroxide 6%, NPN 01936476 by RW Packaging Ltd. Disclosed in part 42
A-2013-00347 Information regarding Calamine Lotion, NPN 00454575 by RW Packaging Ltd. Disclosed in part 49
A-2013-00369 AER for Kaletra. Report number: 000439853. All disclosed 11
A-2013-00372 AERs for Isofulrane. Report numbers: 000445983 and 000444143. All disclosed 12
A-2013-00376 AERs for Humira. Report numbers: 000470927, 000471949, 000472391, 000472826, 000473895, 000473916, 000474334, 000475279, 000476921, 000483144, 000490613, 000489284 and 000489490. Disclosed in part 44
A-2013-00380 Information regarding the medical device Scanscope, License number 91229 by Aperio Technologies Inc. Disclosed in part 38
A-2013-00400 Documents regarding the development and implementation of the new Treasury Board of Canada Secretariat (TBS) Directive on Performance Management and/or related performance appraisal tools. Disclosed in part 513
A-2013-00410 Documents regarding statistics for the number of inspectors/inspections and that indicate how locations for inspections are picked. (Jul 17, 2012 to Jul 16, 2013). Disclosed in part 98
A-2013-00411 All documentation relating to complaints, incidents, warnings, concerns regarding Spray Polyurethane Foam in residential homes from. (Jan 1, 2008 to Jul 16, 2013). Disclosed in part 10
A-2013-00434 All discussions and decisions taken regarding the linguistic profile of all positions in the Office of Regulatory Affairs, in the Biologics and Genetic Therapies Directorate, Health Products and Food Branch. (Apr 1, 2012 to Jul 1, 2013). Disclosed in part 4
A-2013-00474 All written correspondence to/from Pest Management Regulatory Agency from both the bureaucratic and political levels about pesticides, and pollinators. (Apr 1, 2012 to (July 26, 2013). Disclosed in part 30
A-2013-00480 AERs. Report numbers: 000503507 and 000506990. Disclosed in part 3
A-2013-00485 The annual total fee for service transfer to all physicians in Manitoba through the First Nations and Inuit Health Branch funding. (Apr 1, 1998 to Jul 31, 2013). Disclosed in part 302
A-2013-00488 A list of all contracts between Health Canada and the Royal Society of Canada to form an Expert Panel to review literature pertaining to Safety Code 6. Disclosed in part 32
A-2013-00496 Data indicating how much neonicotinoids (insecticide) have been sold in Canada. (Jan 1, 2008 to Aug 2, 2013). Disclosed in part 31
A-2013-00500 Letter from Health Canada to Pharmascience Inc., regarding PMS-OLANZAPINE, stating that the examination of the submission is complete and the Notice of Compliance will not be issued until the requirements of the Patented Medicines Regulations are met. Disclosed in part 2
A-2013-00501 Information regarding APO-OLANZAPINE (20 mg) by Apotex Inc. Disclosed in part 4
A-2013-00511 List of claims that have been approved for probiotic products and the brand names of the products. All disclosed 51
A-2013-00518 Documentation which indicates all appointments term and casual employees by this institution in the National Capital Region under the term of the Public Service Employment Act during July 2013. All disclosed 1
A-2013-00519 Briefing material to the Deputy Minister and the Minister's office related to: the decision to publish an advisory on July 31, 2012 related to potential cancer risk of calcitonin-containing drugs and the decision to pull calcitonin-containing drugs off the market as of October 31, 2013. All disclosed 7
A-2013-00527 AER for Furosemide. Report number: 000498557. Disclosed in part 9
A-2013-00529 AER for Ramipril. Report number: 000502020. Disclosed in part 5
A-2013-00530 AER for Ramipril. Report number: 000385344. Disclosed in part 6
A-2013-00531 AER for Clopidogrel. Report number: 000497910. Disclosed in part 2
A-2013-00532 AER for Clopidogrel. Report number: 000494557. Disclosed in part 2
A-2013-00534 All contracts for Jamie Tibbetts and Michelle Gleeson. (Jan 1, 2010 to Aug 20, 2013). All disclosed 1
A-2013-00538 AER for Docetaxel. Report number: 000491163. Disclosed in part 15
A-2013-00540 AER for Oxaliplatin. Report number: 000503684. Disclosed in part 3
A-2013-00564 All documentation on funds used to send staff or board members at the West Region Tribal Council Office to Hawaii, Las Vegas, and Vancouver. Disclosed in part 36
A-2013-00569 The overall numbers of Valid Licenses and Production Sites that have been authorized to Produce Cannabis (marihuana) by Health Canada under the Marihuana Medical Access Program within various communities of British Columbia. (Aug 1, 2010 to Aug 1, 2013). All disclosed 4
A-2013-00582 The total annual dried cannabis dosage or consumption. (Jan 1, 2013 to Aug 27, 2013). All disclosed 2
A-2013-00583 The total annual dried cannabis dosage or consumption. (Jan 1, 2012 to Dec 31, 2012). All disclosed 2
A-2013-00584 The total annual dried cannabis dosage or consumption. (Jan 1, 2011 to Dec 31, 2011). All disclosed 2
A-2013-00585 The total annual dried cannabis dosage or consumption. (Jan 1, 2010 to Dec 31, 2010). All disclosed 2
A-2013-00586 The total annual dried cannabis dosage or consumption. (Jan 1, 2009 to Dec 31, 2009). All disclosed 2
A-2013-00588 Copy of the forms submitted to the International Narcotics Control Board (INCB) in relation to cannabis (information on the quantities of cannabis to be consumed for medical and scientific purposes). (Jan 1, 2009 to Aug 27, 2013). Disclosed in part 70
A-2013-00589 Copy of the forms submitted to the International Narcotics Control Board (INCB) in relation to cannabis (utilized for the manufacture of other drugs, of preparations in Schedule III). (Jan 1, 2009 to Aug 27, 2013). Disclosed in part 70
A-2013-00590 Copy of the forms submitted to the International Narcotics Control Board (INCB) in relation to cannabis (information on the stocks). (Jan 1, 2009 to Aug 27, 2013). No records exist 0
A-2013-00591 Copy of the forms submitted to the International Narcotics Control Board (INCB) in relation to cannabis (information on the quantities of cannabis necessary for addition to special stocks). (Jan 1, 2009 to Aug 27, 2013). All disclosed 6
A-2013-00595 AER for Enoxaparin. Report number: 000494951. Disclosed in part 4
A-2013-00628 List of all audits, investigations or examinations done by the Non-Insured Health Benefits Directorate of the First Nations and Inuit Health Branch. All disclosed 4
A-2013-00631 List of contracts between Health Canada and Risk Sciences International (RSI). (Jan 1, 1996 to Sep 6, 2013). All disclosed 10
A-2013-00633 All call-ups processed by this institution in the Vancouver region under the terms of the ANY Standing Offer or Supply Arrangement for Temporary Help Services. (Sep 1, 2012 to Aug 1, 2013). Disclosed in part 84
A-2013-00636 All documents related to regulation, legislation, or policy option for limiting or reducing the consumption of sugar in the Canadian population, including sucrose, fructose, high-fructose corn syrup, sugar sweetened drinks and other beverage and food containing sugar.
(May 1, 2009 to Sep 1, 2013).
No records exist 0
A-2013-00638 All documents prepared and sent to the Health minister or to the deputy minister concerning counterfeit products such as Botox or Botox Juverderm. (Apr 1, 2013 to Sep 9, 2013). No records exist 0
A-2013-00642 Copy of the National Anti-Drug Strategy published in 2007. No records exist 0
A-2013-00645 AER for Plaquenil. Report number: 000370370. Disclosed in part 22
A-2013-00646 A listing of the Access to Information requests submitted to Health Canada. (Aug 1, 2013 to Aug 31, 2031). All disclosed 10
A-2013-00648 Reports that disclose the condition Polymyolitis in connection with the aluminum smelter operated by Teck Resources in Trail, British Columbia and/or other smaller operations in Canada. (Sep 13, 2011 to Sep 12, 2013). No records exist 0
A-2013-00656 Document titled Aboriginal Diabetes Initiative Capacity Building Special Study (a notice of proposed procurement was posted on Merx.com on 2013-08-07, solicitation number 1000151403). No records exist 0
A-2013-00658 AER for Eloxatin. Report number: 000509995. Disclosed in part 3
A-2013-00664 AER for Eloxatin. Report number: 000511234. Disclosed in part 3
A-2013-00670 All staff job descriptions within the Veterinary Drugs Directorate that contain the word Policy in the job title. (Sep 1, 2010 to Sep 13, 2013). All disclosed 194
A-2013-00673 Reports for the Veterinary Drugs Directorate relating to cost centre detailed transactions for all codes related to training/travel related to training. (Sep 1, 2010 to Sep 13, 2013). Disclosed in part 10
A-2013-00681 Copy of a list of 16 studies provided by Health Canada to the television show 16:9 "The Bigger Picture" as mentioned in the video clip: http://www.youtube.com/watch?v=KN7VetsCR2I All disclosed 1
A-2013-00689 AERs. Report numbers: 000216932, 000409352, 000309988, 000217110 and 000223195. Disclosed in part 6
A-2013-00692 AERs for Diane-35. Report numbers: 000496734, 000499371, 000499800. 000499818, 000501528 and 000502898. Disclosed in part 12
A-2013-00693 AER for Nexavar. Report number: 000501426. Disclosed in part 4
A-2013-00694 AER for Visanne. Report number: 000498397. Disclosed in part 1
A-2013-00695 AER for Xarelto. Report number: 000498190. Disclosed in part 3
A-2013-00696 AERs for Yasmin. Report numbers: 000496709, 000497219, 000497647, 000497817 and 000499352. Disclosed in part 5
A-2013-00697 AERs for Yaz. Report numbers: 000497216 and 000499430. Disclosed in part 2
A-2013-00698 The total amount of contribution funding provided to each First Nations contribution recipient in Canada from Health Canada. (Apr 1, 2006 to Mar 31, 2013). All disclosed 20
A-2013-00707 Information regarding Ginko Biloba 60mg Soft Gel Capsules, NPN 80003467. Disclosed in part 39
A-2013-00709 AERs relating to Sanofi Pasteur health products. Disclosed in part 13
A-2013-00714 All expense forms, including attached receipts, submitted by or for Kathryn McDade, Assistant Deputy Minister. (Jan 1, 2010 to Sep 24, 2013). No records exist 0
A-2013-00729 Notices received by Pest Management Regulatory Agency (PMRA) from other Organisation for Economic Co-operation and Development (OECD) member countries and/or the OECD Pesticide Program's Working Group on Pesticides, which notify PMRA of any prohibitions of a pest control product by an OECD country. (Sep 26, 2008 to Sep 25, 2013). No records exist 0
A-2013-00746 All documents related to health policies for Canadian citizens who are transgendered. No records exist 0
A-2013-00748 All documents demonstrating the number of employees and the amounts paid annually to your public servants. (Jan 1, 2005 to Sep 30, 2013). All disclosed 6
A-2013-00761 Documents in the Ministerial Executive Correspondence System (number 13-110182-957) sent to the Deputy Minister’s Office dated 2013-06-27. Disclosed in part 34
A-2013-00768 AER. Report number: 000429562. Disclosed in part 1
A-2013-00787 A listing of the Access to Information requests submitted to Health Canada. (Sep 1, 2013 to Sep 30, 2013). Disclosed in part 11
A-2013-00804 Documents related to health and safety inspections by the government at the following commercial property located at 275 Finchdene Square Scarborough, Ontario, M1X 1B9 - Landar Co. Canada Limited and Ascendia Brands Canada Ltd. (Jan 1, 2000 to Oct 11, 2013). No records exist 0
A-2013-00812 All briefing notes, power point presentations, communications and emails to the Minister of Health and Deputy Minister of Health related to the government shutdown in the United States. (Aug 1, 2013 to Oct 16 2013). No records exist 0